secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2026-10-06T20:05:32+00:00
Accession:  0001193125-26-415545
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Kyntra Bio receives Nasdaq delisting determination; requests hearing to remain listed
--------------------------------------------------------------------------------

- Nasdaq Staff determined on Sept 30, 2026 to delist Kyntra Bio (KYNB) after it missed the Sept 29, 2026 deadline to comply with Listing Rule 5450(b).
- Kyntra requested a Nasdaq Hearings Panel review, which stays suspension and Form 25-NSE filing; KYNB continues trading on Nasdaq Global Select Market.
- Company previously got Nasdaq notice on April 2, 2026 for failing Rule 5450(b)(3)(A), which requires at least $50 million in total assets and total revenue.
- An extension period could run up to 180 days from the Staff delisting Determination under Listing Rule 5815(c)(1)(A), but no assurance of relief is given.
- Kyntra Bio is preparing a compliance plan for the Panel; General Counsel John Alden signed on October 6, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/0001193125-26-415545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000119312526415545/kynb-20260930.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer